{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:10:26Z","timestamp":1786723826814,"version":"build-2736575974"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular (CV) health has emerged as an important consideration in patients with chronic myeloid leukemia (CML) because of improved prognosis. Indeed, the success of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has increased the focus on survivorship and late toxicity in oncological care. Survivorship issues in this population include CV disease prevention, given its prevalence in the general population. The introduction of BCR-ABL1 TKIs represented a unique concept of indefinite cancer therapy, only recently evolving to include \u201ctreatment-free remission.\u201d Importantly, later-generation BCR-ABL1 TKIs have been associated with CV complications. Dasatinib has been associated with pleural\/pericardial effusions and pulmonary hypertension, whereas nilotinib and ponatinib have been linked to the development of vascular occlusive events. There is currently a dearth of data with respect to the mechanisms of drug toxicities, the subsets of patients at risk, and prevention and treatment strategies to mitigate CV complications in patients with CML. Nevertheless, optimal patient CV risk assessment needs to become a more central tenet of patient care in CML. We propose several practical considerations for the practicing oncologist relative to the CV health of patients with CML, especially those on chronic TKI therapy.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.110","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"110-114","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy"],"prefix":"10.1182","volume":"2017","author":[{"given":"Mary C.","family":"Barber","sequence":"first","affiliation":[{"name":"Cardiovascular Division,"},{"name":"Cardio-Oncology Program, and"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Cardiovascular Division,"},{"name":"Cardio-Oncology Program, and"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"35","key":"2019111707245003400_B1","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111707245003400_B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"28","key":"2019111707245003400_B3","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111707245003400_B4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111707245003400_B5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111707245003400_B6","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"22","key":"2019111707245003400_B7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111707245003400_B8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111707245003400_B9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111707245003400_B10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"17","key":"2019111707245003400_B11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"2019111707245003400_B12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2019111707245003400_B13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"2019111707245003400_B14","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2019111707245003400_B15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111707245003400_B16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"issue":"5","key":"2019111707245003400_B17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"48","key":"2019111707245003400_B18","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111707245003400_B19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"2019111707245003400_B20","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111707245003400_B21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/eurheartj\/ehu035","article-title":"Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension","volume":"36","author":"Shah","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"2019111707245003400_B22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111707245003400_B23","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111707245003400_B24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2019111707245003400_B25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111707245003400_B26","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111707245003400_B27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111707245003400_B28","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2019111707245003400_B29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111707245003400_B30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2019111707245003400_B31","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.leukres.2011.12.011","article-title":"Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"issue":"7","key":"2019111707245003400_B32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2019111707245003400_B33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"15 Suppl","key":"2019111707245003400_B34","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1200\/jco.2014.32.15_suppl.7081","article-title":"Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial [abstract]","volume":"32","author":"Kantarjian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019111707245003400_B35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"21","key":"2019111707245003400_B36","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood.V124.21.4552.4552","article-title":"Ponatinib efficacy and safety in patients with the T315I mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials [abstract]","volume":"124","author":"Mauro","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111707245003400_B37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/110\/1250515\/hem00015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/110\/1250515\/hem00015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:24:57Z","timestamp":1573993497000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/110\/21105\/Cardiovascular-care-of-patients-with-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.110","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}